|
|
Clinical use of neopterin, a laboratory biomarker of immune activation, in the assessment of prognosis, monitoring response to therapy and complications in cancer patients
Trivedi, Sachin Vipinchandra ; Melichar, Bohuslav (advisor) ; Dvořák, Josef (referee) ; Kocáková, Ilona (referee)
Clinical use of neopterin, a laboratory biomarker of immune activation, in prognosis, monitoring response to therapy and complications in cancer patients Introduction Neopterin is a biomarker of immune activation and is synthesized from GTP in a reaction catalyzed by enzyme GCH-1. Neopterin levels reflect the body's response to inflammatory conditions such as infections, injuries, chronic diseases, and cancer. Its levels also fluctuate with anticancer therapies that demonstrate immune activity. Remarkably neopterin has also been found to be a marker of poor prognosis in cancer. Aim To investigate clinical use of neopterin, a biomarker of immune response, in the assessment of prognosis, monitoring response to therapy, and complications in cancer patients. Methodology In a two-part study, serial urinary neopterin were measured in two different cohorts of patients who underwent anticancer therapy. In part one, samples from 45 patients with diagnosis of metastatic colorectal cancer who were being treated with chemotherapy + cetuximab were analyzed. In part two, samples from 10 patients with diagnosis of gynecological malignancy, mostly cervical cancer undergoing chemoradiotherapy were analyzed. Results In patients with metastatic colorectal carcinoma, higher neopterin levels were associated with poor prognosis....
|
|
|
Clinical use of neopterin, a laboratory biomarker of immune activation, in the assessment of prognosis, monitoring response to therapy and complications in cancer patients
Trivedi, Sachin Vipinchandra ; Melichar, Bohuslav (advisor) ; Dvořák, Josef (referee) ; Kocáková, Ilona (referee)
Clinical use of neopterin, a laboratory biomarker of immune activation, in prognosis, monitoring response to therapy and complications in cancer patients Introduction Neopterin is a biomarker of immune activation and is synthesized from GTP in a reaction catalyzed by enzyme GCH-1. Neopterin levels reflect the body's response to inflammatory conditions such as infections, injuries, chronic diseases, and cancer. Its levels also fluctuate with anticancer therapies that demonstrate immune activity. Remarkably neopterin has also been found to be a marker of poor prognosis in cancer. Aim To investigate clinical use of neopterin, a biomarker of immune response, in the assessment of prognosis, monitoring response to therapy, and complications in cancer patients. Methodology In a two-part study, serial urinary neopterin were measured in two different cohorts of patients who underwent anticancer therapy. In part one, samples from 45 patients with diagnosis of metastatic colorectal cancer who were being treated with chemotherapy + cetuximab were analyzed. In part two, samples from 10 patients with diagnosis of gynecological malignancy, mostly cervical cancer undergoing chemoradiotherapy were analyzed. Results In patients with metastatic colorectal carcinoma, higher neopterin levels were associated with poor prognosis....
|
guest ::
